Abstract:Objective: To identify simple, contemporary predictors of both morbidity and mortality in pediatric patients with purpuric sepsis syndrome in order to provide a basis for future study of innovative interventions. Design: Retrospective study. Setting: An 18-bed multidisciplinary intensive care unit (ICU) in a large pediatric hospital. Patients: A total of 53 patients, ranging in age from 18 days to 17 yrs (mean 4.9 yrs) with either culture-proven meningococcal sepsis or the systemic inflammatory response syndrome with purpura, who were admitted to the ICU during the period from January 1, 1982 through March 15, 1992. Methods: A computerized database was constructed containing the characteristics of these patients at presentation, during the first 24 hrs of hospitalization, and on discharge. Single variables were screened for significance between "good" (intact survival) and "poor" (mortality or survival with significant morbidity) outcome groups. Those variables found to be most significant were then tested for sensitivity, specificity, and predictive value. The best predictors identified in this manner were then compared with the two most-cited prognosticating strategies as applied to these patients. Measurements and main results: Coagulopathy (defined as a partial thromboplastin time > 50 secs or serum fibrinogen concentration < 150 mg/dL [4.4 mumol/L]) at the referral site or on ICU admission was identified as an excellent predictor of poor outcome: sensitivity, specificity, positive and negative predictive values of a low serum fibrinogen value, being 81%, 95%, 93%, and 88%, and of prolonged partial thromboplastin time, being 95%, 90%, 86%, and 97%, respectively. Classical prognosticating strategies were found to be inadequately associated with mortality, yet comparable with coagulopathy in identifying patients destined for clinically important morbidity. Conclusions: We conclude that: a) outcome of pediatric patients with meningococcal sepsis or the systemic inflammatory response syndrome with purpura can be predicted rapidly, more easily, and with overall accuracy superior to classical prognostication strategies by the simple presence or absence of coagulopathy; b) when applied to a contemporary population, classical prognostication strategies lack value for prediction of mortality, yet remain valid for prediction of "poor outcome" (significant morbidity + mortality); c) when evaluating treatment strategies for such patients, the presence of serious coagulopathy may potentially be useful as an index of illness severity.

An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study

Treatment of purpura fulminans in meningococcemia with protein C concentrate

Modulation of Protein C Activation by Histones, Platelet Factor 4, and Heparinoids

Use of protein C concentrate in pediatric patients with sepsis

The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approach.

Dysfunction of endothelial protein C activation in severe meningococcal sepsis

Severe Congenital Protein C Deficiency: Practical Aspects of Management

Application of Percutaneous Cardiopulmonary Support System in Critically Ill Patients

Recombinant Human Activated Protein C for the Treatment of Severe Sepsis and Septic Shock: a Study Protocol for Incorporating Observational Evidence Using a Bayesian Approach.

Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis

Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura

Circulating nucleosomes and severity of illness in children suffering from meningococcal sepsis treated with protein C

Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice

Comprehensive literature review of protein C concentrate use in patients with severe congenital protein C deficiency

Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population

Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia

Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components

Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease

Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge

Role of circulating complement and polymorphonuclear leukocyte transfusion in treatment and outcome in critically ill neonates with sepsis